# iVIEW Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/iview-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Zhuhai, China
- Website: www.iview-cn.com
- Total disclosed funding: $25M
- Latest round: Series A (Jan 17, 2025)
- Investors on record: 5

## About

Established in 2019 and based in Zhuhai, China, iVIEW Therapeutics is a pharmaceutical company that focuses on research and development of ophthalmology, rhinology and dermatology drugs. The company is headquartered in Zhuhai, with a biotech center in Pennsylvania. As of 2022, the company has completed 7 international patents, 15 domestic patents, and 9 publications. The company CSO Dr. Zhu Qi is a postdoctoral fellow at Harvard Medical School and serves as general manager in BMS MI. In January 2025, it closed a series A++ funding.

The company's main business is research and development of ophthalmic, rhinological and dermatological drugs. The company has 3 self-developed technology platforms, including in-situ gel technology platform, nanomicellar technology platforms, and liposome technology platforms. The company's self-developed products include IVIEW-1201, IVIEW-1503, IVIEW-1001, IVIEW-1801, IVIEW-1501, IVIEW-1601, IVIEW-1701 and IVIEW-3601. The IVIEW-1201 for the treatment of acute conjunctivitis and the IVIEW-1503 for the treatment and protection of COVID-19.

iVIEW Therapeutics, Inc. generates revenue by providing innovative topical drugs for ophthalmic, nasal, and dermatological treatments to the pharmaceutical market.

The company will use the series A++ funding for the clinical trial and registration of IVW-1001, a first-in-class innovative chemical drug developed for the treatment of dry eye disease with an innovative target. In addition, it expects to submit a clinical phase III application for the treatment of adenoviral conjunctivitis at the FDA in 2025.

## Funding rounds

- Series A, Jan 17, 2025 — 3JS Investments, Proxima Ventures, Dianshi Huayi Capital, Hangzhou Yilu Medical Equipment Co., Ltd
- Series A, Jan 20, 2022, $25M — Cowin Capital

## Investors

- Cowin Capital (https://capitalatlas.ai/funds/cowin-capital) — Series A
- 3JS Investments — Series A
- Proxima Ventures (https://capitalatlas.ai/funds/proxima-ventures) — Series A
- Dianshi Huayi Capital (https://capitalatlas.ai/funds/dianshi-huayi-capital) — Series A
- Hangzhou Yilu Medical Equipment Co., Ltd — Series A